In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Welcome to Outlook 2021. The year 2020 was full of disruption: a global pandemic rocked the world, ground-breaking R&D efforts came to fruition for the biopharmaceutical and medtech sectors at record speeds, virtual became reality and global political events encroached on health care systems. Looking ahead into 2021 is tricky. No one could have predicted the events of the past 12 months, and the year ahead will certainly throw surprises at the life sciences sector.

Amongst the upheaval, our team of journalists and analysts has come together for Outlook 2021, to provide insight and scrutiny on various trends and topics critical to life sciences decision-makers.

Outlook 2021 also includes the annual Scrip 100, Medtech 100 and Generics Bulletin Top 50 league tables – evaluating the performance of the pharma and medtech sectors throughout fiscal year 2019. Check out the new ‘Industry Data’ tab to find out more.

Lucie Ellis
Executive Editor, In Vivo

Setting The Scene

2021 Biopharma Outlook: Turning Uncertainty Into Opportunity

A singular focus on defeating COVID-19 will likely dominate the biopharma agenda at the beginning of 2021 and will determine how quickly the industry, and world, can bounce back to something like normalcy. New digital capabilities and learnings will continue to emerge as the pandemic ebbs, and strong industry balance sheets will keep the deal volume moving, according to experts and executives.

Into 2021 Medtechs Prioritize Third-Wave Coronavirus Readiness

Coronavirus has definitively changed health care delivery and the perceptions of health technologies and digital ecosystems. Industry will need to adjust to the aftermath of COVID-19, take opportunities and learn lessons from 2020 or 2021 could be every inch as challenging.